18F-FDG PET/CT显示免疫联合靶向治疗未分化甲状腺癌显著缓解
本文报道一例51岁女性活检证实的未分化甲状腺癌患者,初诊时存在广泛局部区域病变和肺转移,接受帕博利珠单抗联合仑伐替尼治疗后,用18F-FDG PET/CT评估疗效,显示接近完全代谢缓解。未分化甲状腺癌罕见且侵袭性强、预后差、对常规治疗反应有限,靶向与免疫治疗近年显示改善预后的潜力,18F-FDG PET/CT可用于评估病变范围和监测治疗反应。
要点
- 未分化甲状腺癌侵袭性强、预后差,常规治疗反应有限。
- 靶向联合免疫治疗在该例中显示接近完全代谢缓解。
- 18F-FDG PET/CT可用于评估病变范围和监测疗效。
核心结论
- 一例未分化甲状腺癌患者接受帕博利珠单抗联合仑伐替尼治疗后,18F-FDG PET/CT显示接近完全代谢缓解。
研究设计与样本
- 本文为个案报道,对象为一名51岁女性,活检证实为未分化甲状腺癌。
主要发现
- 该患者初诊时存在广泛局部区域病变和肺转移。
- 接受帕博利珠单抗联合仑伐替尼治疗后,18F-FDG PET/CT疗效评估显示接近完全代谢缓解。
临床怎么用
- 18F-FDG PET/CT可作为未分化甲状腺癌评估病变范围和监测治疗反应的工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive malignancy with a dismal prognosis and limited responsiveness to conventional therapies. Recent advances in targeted therapy and immunotherapy have shown promise in improving outcomes. 18 F-FDG PET/CT serves as a valuable tool for evaluating disease extent and monitoring therapeutic response in ATC. We present the case of a 51-year-old woman diagnosed with biopsy-proven anaplastic thyroid carcinoma, presenting with extensive locoregional disease and pulmonary metastases on Pembrolizumab and Lenvatinib. 18 F-FDG PET/CT was done for response assessment which showed near complete metabolic response.
引用
- Dharmashaktu Y, Rastogi S, Wakankar R, et al. 18 F-FDG PET/CT Demonstrates Significant Response in Anaplastic Thyroid Carcinoma Treated With Combined Immunotherapy and Targeted Therapy. Clin Nucl Med. 2026. PMID: 41739501. doi:10.1097/RLU.0000000000006207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。